Sep 25 2026 01:23 PM EST

Altria Narrows 2026 EPS Guidance as Smoke‑Free Portfolio Grows

Altria Group, Inc. (NYSE: MO) reported second‑quarter 2026 net revenues of $6.11 billion, essentially flat year‑over‑year, and adjusted diluted earnings per share of $1.48, up 2.8% YoY but $0.02 below consensus. The company also raised its quarterly dividend to $1.11 per share, an annualized yield of roughly 6.4%, and narrowed full‑year adjusted EPS guidance to $5.61‑$5.72.

Quarter Results and Guidance

Net revenues were up 0.1% YoY, while revenues net of excise taxes rose 1.2%. Reported diluted EPS fell 2.8% to $1.37. Adjusted diluted EPS of $1.48 beat the consensus estimate of $1.50 by $0.02. The company returned roughly $3.9 billion to shareholders in the first half through dividends and share repurchases.

Idiosyncratic Drivers

Altria’s smoke‑free portfolio expanded with the rollout of on! PLUS to 120,000 stores nationwide. The company also advanced its partnership with Philip Morris International on heated‑tobacco products and continued to market NJOY ACE e‑vapor devices, although the FDA’s review process remains a constraint. Cost‑saving initiatives under the “Optimize & Accelerate” program are expected to improve margins and are cited as a source of future earnings growth.

The USSTC Facilities Consolidation generated an asset‑impairment charge of roughly $0.04 per share in Q2, but management expects the consolidation to deliver long‑term efficiency gains.

Macro Context

The broader U.S. tobacco market continues to face volume pressure from persistent inflation and discretionary‑spending constraints, prompting many adult smokers to trade down to discount brands. The discount‑cigarette segment now accounts for a record 33.3% of the market in Q1 2026. Altria’s guidance assumes a “progressive cigarette import/export activity” in the second half of 2026, which could offset some volume decline.

Regulatory headwinds remain pronounced. The FDA continues litigation over nicotine‑pouch review processes, has imposed menthol‑cigarette restrictions, and is scrutinizing the illicit e‑vapor market. While the agency has authorized several Altria nicotine‑pouch flavors (on! PLUS) and menthol e‑cigarettes via NJOY, the overall review timeline adds uncertainty to the rollout of new smoke‑free products.

Strategic Outlook

Altria’s “Moving Beyond Smoking” strategy targets a double‑digit increase in smoke‑free net revenue by 2028, with on! PLUS positioned as the flagship oral‑nicotine franchise. The company’s capital‑expenditure plan for 2026 has been raised to $375‑$450 million to support the USSTC consolidation and capacity upgrades for next‑generation products.

Financially, Altria’s trailing‑12‑month operating margin improved to 59.9% in Q2 2026, up from 54.6% in the prior year, reflecting higher pricing power and the contribution of higher‑margin smoke‑free products.

Risks and Uncertainties

Key risks include continued secular decline in combustible‑cigarette volumes, which could outpace price‑increase offsets; potential adverse FDA rulings on nicotine‑pouch and e‑vapor products; and the possibility that the anticipated import/export boost in H2 2026 does not materialize. The higher dividend payout—approximately 80% of adjusted EPS—limits retained earnings for reinvestment, making the execution of the smoke‑free roadmap critical to sustaining earnings growth.

Investors will also watch the outcome of the “Optimize & Accelerate” cost‑savings program and any further asset‑impairment charges linked to the USSTC consolidation, as these could affect near‑term profitability.